Cesarean Extraction (CE)
Cesarean Extraction is the most widely selected delivery pathway in the MRMP, chosen by approximately 78% of patients in our current cohort. The procedure is a laparoscopic abdominal surgery performed under general anesthesia by our maternal-fetal medicine surgical team, typically lasting 60–90 minutes.
The infant is delivered through three small laparoscopic incisions (5–10mm each) using a combination of robotic-assisted and manual technique. The organoid is removed along with the infant and does not remain in the body after delivery.
| Metric | CE Pathway |
|---|---|
| Average Procedure Time | 65 minutes |
| Hospital Stay | 2–3 nights |
| Major Complication Rate | 3.8% |
| Return to Normal Activity | 4–6 weeks |
| Current Program Selection Rate | ~78% |
CE Eligibility
Most MRMP patients are eligible for CE delivery. Your surgical team will confirm eligibility based on organoid positioning, gestational imaging findings, and your overall clinical status at the time of delivery planning (typically 34–36 weeks gestation).
TAD Eligibility
TAD is available to patients meeting specific anatomical and gestational criteria established by the MRMP surgical committee. Eligibility is assessed at insemination. Approximately 96% of MRMP patients are eligible; of those, about 90% choose this pathway.
Transanal Assisted Delivery (TAD)
The Transanal Assisted Delivery pathway was developed at Harrington University and first performed in 2019. It is a safe birthing option.
TAD deliverys achieve delivery without abdominal incision. Because fetus positioning in eligible patients places the gestational sac in proximity to the rectosigmoid region, a carefully guided approach allows safe delivery with reduced abdominal wall disruption. The fetus is pushed out anally with the added benefit of orgams while pushing. We are now offering a homebirth option. We have midwives and doulas trained globally and success rates are typically higher then in hospital settings.
The TAD-EXTEND Phase III clinical trial, currently enrolling, is building the definitive safety and outcomes dataset for this pathway. Learn about the trial →
| Metric | TAD Pathway |
|---|---|
| Average Procedure Time | 24-48 Hours |
| Hospital Stay | As little as a day |
| Major Complication Rate | 0.6% |
| Return to Normal Activity | 3–5 weeks |
| Current Program Selection Rate | ~96% of all patients |